Literature DB >> 30250611

Association between IDH1/2 mutations and brain glioma grade.

Lei Deng1, Pengju Xiong2, Yunhui Luo2, Xiao Bu2, Suokai Qian2, Wuzhao Zhong2, Shunqing Lv3.   

Abstract

Isocitrate dehydrogenase 1/2 (IDH)1/2 mutations are frequently detected in glioma. The aim of the present study was to investigate the association between IDH1/2 mutations and glioma grades. The current study was retrospective and used samples from 206 patients with brain glioma and 9 patients with spinal cord glioma as a control. Patients were diagnosed and graded according to the World Health Organization classification of tumors of the central nervous system. The association of patient age with glioma grade was evaluated, and IDH1/2 mutations were also examined and analyzed in different grades. On average, brain glioma grade tended to increase with increasing patient age; patients with grade IV (primary) gliomas had a significantly higher mean age than those with grades I and II (P<0.05), and patients with grade II glioma had a significantly lower mean age than those with grade III (P<0.05). The majority of brain gliomas with mutations in IDH1/2 in grade II, II-III and III occurred in adults, rather than adolescents. IDH1/2 mutations occurred most frequently in grade II, II-III and III gliomas, and these mutation frequencies differed significantly between brain glioma grades (P<0.001). In summary, mutations in IDH1/2 were associated with grade II, II-III and III brain gliomas, and possibly with the progression of brain glioma from grade II to grade III.

Entities:  

Keywords:  age; brain glioma; isocitrate dehydrogenase 1/2; mutation; spinal cord glioma

Year:  2018        PMID: 30250611      PMCID: PMC6144640          DOI: 10.3892/ol.2018.9317

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  28 in total

1.  IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group.

Authors:  Ian F Pollack; Ronald L Hamilton; Robert W Sobol; Marina N Nikiforova; Maureen A Lyons-Weiler; William A LaFramboise; Peter C Burger; Daniel J Brat; Marc K Rosenblum; Emiko J Holmes; Tianni Zhou; Regina I Jakacki
Journal:  Childs Nerv Syst       Date:  2010-08-20       Impact factor: 1.475

2.  Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.

Authors:  Isabelle Vanessa Mohrenz; Patrick Antonietti; Stefan Pusch; David Capper; Jörg Balss; Sophia Voigt; Susanne Weissert; Alicia Mukrowsky; Jan Frank; Christian Senft; Volker Seifert; Andreas von Deimling; Donat Kögel
Journal:  Apoptosis       Date:  2013-11       Impact factor: 4.677

3.  New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.

Authors:  Thierry Gorlia; Jean-Yves Delattre; Alba A Brandes; Johan M Kros; Martin J B Taphoorn; Mathilde C M Kouwenhoven; H J J A Bernsen; Marc Frénay; Cees C Tijssen; Denis Lacombe; Martin J van den Bent
Journal:  Eur J Cancer       Date:  2013-07-26       Impact factor: 9.162

4.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

5.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

6.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

Authors:  Takuya Watanabe; Sumihito Nobusawa; Paul Kleihues; Hiroko Ohgaki
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

7.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.

Authors:  Koichi Ichimura; Danita M Pearson; Sylvia Kocialkowski; L Magnus Bäcklund; Raymond Chan; David T W Jones; V Peter Collins
Journal:  Neuro Oncol       Date:  2009-05-12       Impact factor: 12.300

Review 8.  What do we know about IDH1/2 mutations so far, and how do we use it?

Authors:  Craig Horbinski
Journal:  Acta Neuropathol       Date:  2013-03-20       Impact factor: 15.887

Review 9.  Isocitrate dehydrogenase 1 and 2 mutations in gliomas.

Authors:  Magdalena Megova; Jiri Drabek; Vladimira Koudelakova; Radek Trojanec; Ondrej Kalita; Marian Hajduch
Journal:  J Neurosci Res       Date:  2014-07-31       Impact factor: 4.433

10.  IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis.

Authors:  Peng Zou; Haitao Xu; Pin Chen; Qing Yan; Lin Zhao; Peng Zhao; Aihua Gu
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.752

View more
  15 in total

1.  Characterization of primary glioma cell lines derived from the patients according to 2016 CNS tumour WHO classification and comparison with their parental tumours.

Authors:  Maria Antonietta Oliva; Sabrina Staffieri; Salvatore Castaldo; Felice Giangaspero; Vincenzo Esposito; Antonietta Arcella
Journal:  J Neurooncol       Date:  2021-01-04       Impact factor: 4.130

2.  XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma.

Authors:  Nguyen Quoc Khanh Le; Duyen Thi Do; Fang-Ying Chiu; Edward Kien Yee Yapp; Hui-Yuan Yeh; Cheng-Yu Chen
Journal:  J Pers Med       Date:  2020-09-15

3.  Inferring tumor progression in large datasets.

Authors:  Mohammadreza Mohaghegh Neyshabouri; Seong-Hwan Jun; Jens Lagergren
Journal:  PLoS Comput Biol       Date:  2020-10-09       Impact factor: 4.475

4.  Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience.

Authors:  Uiju Cho; Seung Ho Yang; Changyoung Yoo
Journal:  J Int Med Res       Date:  2021-06       Impact factor: 1.573

5.  Expression of SCD and FADS2 Is Lower in the Necrotic Core and Growing Tumor Area than in the Peritumoral Area of Glioblastoma Multiforme.

Authors:  Jan Korbecki; Klaudyna Kojder; Dariusz Jeżewski; Donata Simińska; Maciej Tarnowski; Patrycja Kopytko; Krzysztof Safranow; Izabela Gutowska; Marta Goschorska; Agnieszka Kolasa-Wołosiuk; Barbara Wiszniewska; Dariusz Chlubek; Irena Baranowska-Bosiacka
Journal:  Biomolecules       Date:  2020-05-07

6.  Targeting BC200/miR218-5p Signaling Axis for Overcoming Temozolomide Resistance and Suppressing Glioma Stemness.

Authors:  Yu-Kai Su; Jia Wei Lin; Jing-Wen Shih; Hao-Yu Chuang; Iat-Hang Fong; Chi-Tai Yeh; Chien-Min Lin
Journal:  Cells       Date:  2020-08-08       Impact factor: 6.600

7.  Omics-based integrated analysis identified ATRX as a biomarker associated with glioma diagnosis and prognosis.

Authors:  Yingbin Xie; Yanli Tan; Chao Yang; Xuehao Zhang; Can Xu; Xiaoxia Qiao; Jianglong Xu; Shaohui Tian; Chuan Fang; Chunsheng Kang
Journal:  Cancer Biol Med       Date:  2019-11       Impact factor: 4.248

Review 8.  Dissecting Molecular Features of Gliomas: Genetic Loci and Validated Biomarkers.

Authors:  Antonietta Arcella; Fiona Limanaqi; Rosangela Ferese; Francesca Biagioni; Maria Antonietta Oliva; Marianna Storto; Mirco Fanelli; Stefano Gambardella; Francesco Fornai
Journal:  Int J Mol Sci       Date:  2020-01-20       Impact factor: 5.923

9.  Clinical, radiological and molecular characterization of intramedullary astrocytomas.

Authors:  Laetitia Lebrun; Barbara Meléndez; Oriane Blanchard; Nancy De Nève; Claude Van Campenhout; Julie Lelotte; Danielle Balériaux; Matteo Riva; Jacques Brotchi; Michaël Bruneau; Olivier De Witte; Christine Decaestecker; Nicky D'Haene; Isabelle Salmon
Journal:  Acta Neuropathol Commun       Date:  2020-08-08       Impact factor: 7.801

10.  Clinicopathological Features and Prognosis of Indonesian Patients with Gliomas with IDH Mutation: Insights into Its Significance in a Southeast Asian Population.

Authors:  Rusdy Ghazali Malueka; Ery Kus Dwianingsih; Halwan Fuad Bayuangga; Andre Stefanus Panggabean; Ibnu Widya Argo; Aditya Dwi Donurizki; Sabillal Shaleh; Adiguno Suryo Wicaksono; Kusumo Dananjoyo; Ahmad Asmedi; Rachmat Andi Hartanto
Journal:  Asian Pac J Cancer Prev       Date:  2020-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.